Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy of Intradermal Hepatitis B Vaccine in Renal Failure Patients

Trial Profile

Efficacy of Intradermal Hepatitis B Vaccine in Renal Failure Patients

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 01 Jul 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Hepatitis B vaccine (Primary) ; Hepatitis B vaccine (Primary) ; Imiquimod
  • Indications Hepatitis B
  • Focus Pharmacodynamics

Most Recent Events

  • 01 Jul 2020 New trial record
  • 18 Jun 2020 Primary endpoint (Seroprotection rate to HBV) has been met according to the results published in the Clinical Infectious Diseases
  • 18 Jun 2020 Results assessing the immunogenicity and safety of topical pretreatment with TLR7 agonist imiquimod before ID HBVv in patients on dialysis published in the Clinical Infectious Diseases

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top